Thus, A2AR antagonism may alleviate schizophrenia symptoms by two complementary mechanisms: acutely via inhibition of enhanced GDNF-driven striatal dopamine release and chronically via downregulation of striatal GDNF expression (Fig. 8). The gene discussed is GDNF; the disease is schizophrenia.